Targeting CLPTM1L for treatment and prevention of cancer
US10266586B2 · kind B2 · utility
1Cited by
14References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 6, 2015 |
| Grant date | Apr 23, 2019 |
| Priority date | — |
| Expiry date | Jan 6, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.